schliessen

Filtern

 

Bibliotheken

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Summary Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic str... Full description

Journal Title: The Lancet (British edition) 2015, Vol.385 (9984), p.2272-2279
Main Author: Zhu, Feng-Cai, MSc
Other Authors: Hou, Li-Hua, PhD , Li, Jing-Xin, MSc , Wu, Shi-Po, PhD , Liu, Pei, Prof , Zhang, Gui-Rong, PhD , Hu, Yue-Mei, BSc , Meng, Fan-Yue, MSc , Xu, Jun-Jie, PhD , Tang, Rong, MSc , Zhang, Jin-Long, PhD , Wang, Wen-Juan, MSc , Duan, Lei, MSc , Chu, Kai, MSc , Liang, Qi, MSc , Hu, Jia-Lei, MSc , Luo, Li, MSc , Zhu, Tao, PhD , Wang, Jun-Zhi, PhD , Chen, Wei, Dr
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/25817373
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1690210729
title: Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
format: Article
creator:
  • Zhu, Feng-Cai, MSc
  • Hou, Li-Hua, PhD
  • Li, Jing-Xin, MSc
  • Wu, Shi-Po, PhD
  • Liu, Pei, Prof
  • Zhang, Gui-Rong, PhD
  • Hu, Yue-Mei, BSc
  • Meng, Fan-Yue, MSc
  • Xu, Jun-Jie, PhD
  • Tang, Rong, MSc
  • Zhang, Jin-Long, PhD
  • Wang, Wen-Juan, MSc
  • Duan, Lei, MSc
  • Chu, Kai, MSc
  • Liang, Qi, MSc
  • Hu, Jia-Lei, MSc
  • Luo, Li, MSc
  • Zhu, Tao, PhD
  • Wang, Jun-Zhi, PhD
  • Chen, Wei, Dr
subjects:
  • Abridged Index Medicus
  • Adenoviruses
  • Adolescent
  • Adult
  • Clinical trials
  • Clinical Trials, Phase I as Topic
  • Ebola Vaccines - administration & dosage
  • Ebola Vaccines - immunology
  • Ebola virus
  • Ebolavirus - immunology
  • Female
  • Glycoproteins - immunology
  • Humans
  • Immunogenetic Phenomena
  • Internal Medicine
  • Male
  • Middle Aged
  • Pilot Projects
  • Product development
  • Vaccines
  • Young Adult
ispartof: The Lancet (British edition), 2015, Vol.385 (9984), p.2272-2279
description: Summary Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov , number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7120028
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1690210729
sourceformatXML
sourcesystemPC
galeidA419845612
sourcerecordidA419845612
originalsourceidFETCH-LOGICAL-1744t-b0d94b1c2e91c3b6cb92e3f36d06abda4fe2a57596ccbc3b859b6cded37a2c9d3
addsrcrecordideNqFkm1r1TAUx4sobk4_gpJXMmGdSdu0q4IyxnyAgS-m4LuQh9N7M9OkJumF-yH9Tp676pxDkEKbHH7nf87p-RfFU0aPGWXty0vKGlq2Xd0eMv6ipZzXJb1X7LOma0redF_vF_s3yF7xKKUrSmmD4MNir-InrKu7er_4cSkHyFsivSF2HGcfVuCtthgKA5HEhw04EkGHUVkvfSbSAAZtnBPJ2wlKTjagc4ilkgkMOVfBSbKRWlsPxHqyBunyGiuY2eW0i5ytUekVmSI4O-IxbrHAFGJeSkbsJYwWxY6ICbNyUCpnPd4mJzWoUOrgcwzO7YhpjWUJIzla6R4XDwbpEjz59T0ovrw7_3z2obz49P7j2elFybqmyaWipm8U0xX0TNeq1aqvoB7q1tBWKiObASrJO963WisETniPkAFTd7LSvakPisNFd4rh-wwpC-xXg3PSQ5iTYG1PK0a7qkf0eEFX0oGwfgg5So2PgdHiIDBYjJ82rD9peMsqTHj2jwRxG3h-C1h-bwpuzjb49LfS0S1QzQk3kvCV7Gqd00rO6Q7OF1zHkFKEQUzRjrgdwajYeU5ce07sDCUYF9eeE_RPw9OsRjA3Wb9NhsDrO8LoL7lrFyez7r_yb5dswIVuLESRtAWvwVi0ZRYm2P8qvLmjoNFPVkv3DbaQrsIcPbpFMJEqQReRnQbj1wq0_gnqmQ_H
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1690210729
display
typearticle
titleSafety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
sourceAlma/SFX Local Collection
creatorZhu, Feng-Cai, MSc ; Hou, Li-Hua, PhD ; Li, Jing-Xin, MSc ; Wu, Shi-Po, PhD ; Liu, Pei, Prof ; Zhang, Gui-Rong, PhD ; Hu, Yue-Mei, BSc ; Meng, Fan-Yue, MSc ; Xu, Jun-Jie, PhD ; Tang, Rong, MSc ; Zhang, Jin-Long, PhD ; Wang, Wen-Juan, MSc ; Duan, Lei, MSc ; Chu, Kai, MSc ; Liang, Qi, MSc ; Hu, Jia-Lei, MSc ; Luo, Li, MSc ; Zhu, Tao, PhD ; Wang, Jun-Zhi, PhD ; Chen, Wei, Dr
creatorcontribZhu, Feng-Cai, MSc ; Hou, Li-Hua, PhD ; Li, Jing-Xin, MSc ; Wu, Shi-Po, PhD ; Liu, Pei, Prof ; Zhang, Gui-Rong, PhD ; Hu, Yue-Mei, BSc ; Meng, Fan-Yue, MSc ; Xu, Jun-Jie, PhD ; Tang, Rong, MSc ; Zhang, Jin-Long, PhD ; Wang, Wen-Juan, MSc ; Duan, Lei, MSc ; Chu, Kai, MSc ; Liang, Qi, MSc ; Hu, Jia-Lei, MSc ; Luo, Li, MSc ; Zhu, Tao, PhD ; Wang, Jun-Zhi, PhD ; Chen, Wei, Dr
descriptionSummary Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov , number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7–711·3] and 820·5 [598·9–1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3–1098·5] and 1305·7 [970·1–1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0–1202·5) in participants in the low-dose group and 765·0 cells (400·0–1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Interpretation Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days. Funding China National Science and Technology, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(15)60553-0
3PMID: 25817373
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Adenoviruses ; Adolescent ; Adult ; Clinical trials ; Clinical Trials, Phase I as Topic ; Ebola Vaccines - administration & dosage ; Ebola Vaccines - immunology ; Ebola virus ; Ebolavirus - immunology ; Female ; Glycoproteins - immunology ; Humans ; Immunogenetic Phenomena ; Internal Medicine ; Male ; Middle Aged ; Pilot Projects ; Product development ; Vaccines ; Young Adult
ispartofThe Lancet (British edition), 2015, Vol.385 (9984), p.2272-2279
rights
0Elsevier Ltd
12015 Elsevier Ltd
2Copyright © 2015 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2015 Elsevier B.V.
lds50peer_reviewed
citedbyFETCH-LOGICAL-1744t-b0d94b1c2e91c3b6cb92e3f36d06abda4fe2a57596ccbc3b859b6cded37a2c9d3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25817373$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Zhu, Feng-Cai, MSc
1Hou, Li-Hua, PhD
2Li, Jing-Xin, MSc
3Wu, Shi-Po, PhD
4Liu, Pei, Prof
5Zhang, Gui-Rong, PhD
6Hu, Yue-Mei, BSc
7Meng, Fan-Yue, MSc
8Xu, Jun-Jie, PhD
9Tang, Rong, MSc
10Zhang, Jin-Long, PhD
11Wang, Wen-Juan, MSc
12Duan, Lei, MSc
13Chu, Kai, MSc
14Liang, Qi, MSc
15Hu, Jia-Lei, MSc
16Luo, Li, MSc
17Zhu, Tao, PhD
18Wang, Jun-Zhi, PhD
19Chen, Wei, Dr
title
0Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov , number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7–711·3] and 820·5 [598·9–1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3–1098·5] and 1305·7 [970·1–1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0–1202·5) in participants in the low-dose group and 765·0 cells (400·0–1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Interpretation Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days. Funding China National Science and Technology, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology.
subject
0Abridged Index Medicus
1Adenoviruses
2Adolescent
3Adult
4Clinical trials
5Clinical Trials, Phase I as Topic
6Ebola Vaccines - administration & dosage
7Ebola Vaccines - immunology
8Ebola virus
9Ebolavirus - immunology
10Female
11Glycoproteins - immunology
12Humans
13Immunogenetic Phenomena
14Internal Medicine
15Male
16Middle Aged
17Pilot Projects
18Product development
19Vaccines
20Young Adult
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqFkm1r1TAUx4sobk4_gpJXMmGdSdu0q4IyxnyAgS-m4LuQh9N7M9OkJumF-yH9Tp676pxDkEKbHH7nf87p-RfFU0aPGWXty0vKGlq2Xd0eMv6ipZzXJb1X7LOma0redF_vF_s3yF7xKKUrSmmD4MNir-InrKu7er_4cSkHyFsivSF2HGcfVuCtthgKA5HEhw04EkGHUVkvfSbSAAZtnBPJ2wlKTjagc4ilkgkMOVfBSbKRWlsPxHqyBunyGiuY2eW0i5ytUekVmSI4O-IxbrHAFGJeSkbsJYwWxY6ICbNyUCpnPd4mJzWoUOrgcwzO7YhpjWUJIzla6R4XDwbpEjz59T0ovrw7_3z2obz49P7j2elFybqmyaWipm8U0xX0TNeq1aqvoB7q1tBWKiObASrJO963WisETniPkAFTd7LSvakPisNFd4rh-wwpC-xXg3PSQ5iTYG1PK0a7qkf0eEFX0oGwfgg5So2PgdHiIDBYjJ82rD9peMsqTHj2jwRxG3h-C1h-bwpuzjb49LfS0S1QzQk3kvCV7Gqd00rO6Q7OF1zHkFKEQUzRjrgdwajYeU5ce07sDCUYF9eeE_RPw9OsRjA3Wb9NhsDrO8LoL7lrFyez7r_yb5dswIVuLESRtAWvwVi0ZRYm2P8qvLmjoNFPVkv3DbaQrsIcPbpFMJEqQReRnQbj1wq0_gnqmQ_H
startdate2015
enddate2015
creator
0Zhu, Feng-Cai, MSc
1Hou, Li-Hua, PhD
2Li, Jing-Xin, MSc
3Wu, Shi-Po, PhD
4Liu, Pei, Prof
5Zhang, Gui-Rong, PhD
6Hu, Yue-Mei, BSc
7Meng, Fan-Yue, MSc
8Xu, Jun-Jie, PhD
9Tang, Rong, MSc
10Zhang, Jin-Long, PhD
11Wang, Wen-Juan, MSc
12Duan, Lei, MSc
13Chu, Kai, MSc
14Liang, Qi, MSc
15Hu, Jia-Lei, MSc
16Luo, Li, MSc
17Zhu, Tao, PhD
18Wang, Jun-Zhi, PhD
19Chen, Wei, Dr
general
0Elsevier Ltd
1Elsevier B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
107X8
sort
creationdate2015
titleSafety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
authorZhu, Feng-Cai, MSc ; Hou, Li-Hua, PhD ; Li, Jing-Xin, MSc ; Wu, Shi-Po, PhD ; Liu, Pei, Prof ; Zhang, Gui-Rong, PhD ; Hu, Yue-Mei, BSc ; Meng, Fan-Yue, MSc ; Xu, Jun-Jie, PhD ; Tang, Rong, MSc ; Zhang, Jin-Long, PhD ; Wang, Wen-Juan, MSc ; Duan, Lei, MSc ; Chu, Kai, MSc ; Liang, Qi, MSc ; Hu, Jia-Lei, MSc ; Luo, Li, MSc ; Zhu, Tao, PhD ; Wang, Jun-Zhi, PhD ; Chen, Wei, Dr
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1744t-b0d94b1c2e91c3b6cb92e3f36d06abda4fe2a57596ccbc3b859b6cded37a2c9d3
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Abridged Index Medicus
1Adenoviruses
2Adolescent
3Adult
4Clinical trials
5Clinical Trials, Phase I as Topic
6Ebola Vaccines - administration & dosage
7Ebola Vaccines - immunology
8Ebola virus
9Ebolavirus - immunology
10Female
11Glycoproteins - immunology
12Humans
13Immunogenetic Phenomena
14Internal Medicine
15Male
16Middle Aged
17Pilot Projects
18Product development
19Vaccines
20Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Zhu, Feng-Cai, MSc
1Hou, Li-Hua, PhD
2Li, Jing-Xin, MSc
3Wu, Shi-Po, PhD
4Liu, Pei, Prof
5Zhang, Gui-Rong, PhD
6Hu, Yue-Mei, BSc
7Meng, Fan-Yue, MSc
8Xu, Jun-Jie, PhD
9Tang, Rong, MSc
10Zhang, Jin-Long, PhD
11Wang, Wen-Juan, MSc
12Duan, Lei, MSc
13Chu, Kai, MSc
14Liang, Qi, MSc
15Hu, Jia-Lei, MSc
16Luo, Li, MSc
17Zhu, Tao, PhD
18Wang, Jun-Zhi, PhD
19Chen, Wei, Dr
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Zhu, Feng-Cai, MSc
1Hou, Li-Hua, PhD
2Li, Jing-Xin, MSc
3Wu, Shi-Po, PhD
4Liu, Pei, Prof
5Zhang, Gui-Rong, PhD
6Hu, Yue-Mei, BSc
7Meng, Fan-Yue, MSc
8Xu, Jun-Jie, PhD
9Tang, Rong, MSc
10Zhang, Jin-Long, PhD
11Wang, Wen-Juan, MSc
12Duan, Lei, MSc
13Chu, Kai, MSc
14Liang, Qi, MSc
15Hu, Jia-Lei, MSc
16Luo, Li, MSc
17Zhu, Tao, PhD
18Wang, Jun-Zhi, PhD
19Chen, Wei, Dr
formatjournal
genrearticle
ristypeJOUR
atitleSafety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
jtitleThe Lancet (British edition)
addtitleLancet
date2015
risdate2015
volume385
issue9984
spage2272
epage2279
pages2272-2279
issn0140-6736
eissn1474-547X
abstractSummary Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov , number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7–711·3] and 820·5 [598·9–1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3–1098·5] and 1305·7 [970·1–1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0–1202·5) in participants in the low-dose group and 765·0 cells (400·0–1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Interpretation Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days. Funding China National Science and Technology, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology.
copEngland
pubElsevier Ltd
pmid25817373
doi10.1016/S0140-6736(15)60553-0